CLAIMS

1. A compound according to Formula (I):



(I)

Wherein

X is absent or present and when present is selected from the group consisting of C(O), C(S), $S(O)_2$, $(CR^7R^8)_n$, O, N, NR^1, S and S(O);

Y is absent or present and when present is $(CR^7R^8)_n$;

Z is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, and alkynyl, $(CR^{10}R^{11})_oNR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oO(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oS(O)_n(CR^{12}R^{13})_p$ and cycloalkyl;

W is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, OR^9, O, NR^9R^{10} , NR^9, CR^9, CR^9R^{10},

$C(O)R^9$, $C(O)NR^9$, $NR^9C(O)$, $C(O)NR^9R^{10}$, $NR^9R^{10}C(O)$, $C(O)OR^9$, $OC(O)R^9$ and heterocycloalkyl;

Q is absent or present and when present is selected from O, S, NR^1, CR^1, $(CR^{14}R^{15})_t$, C(O) and cycloalkyl;

ring 

is selected from the group consisting of monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, monocyclic carbocyclic, multicyclic carbocyclic, monocyclic heterocyclic, and multicyclic heterocyclic ring systems;

the bond between Q and X is a single or double bond;

R^1 is selected from hydrogen, alkyl, cycloalkyl, haloalkyl, heteroalkyl, heterohaloalkyl and heteroalkynyl;

R^2 is selected from hydrogen, deuterium, halogen, CN, alkyl, cycloalkyl, haloalkyl, heteroalkyl, aryl, heteroaryl, heterohaloalkyl and heteroalkynyl;

R^3 is independently selected from the group consisting of: hydrogen, deuterium, halogen, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl and C(O);

R^4 is independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxyl, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl,

arylalkenyl, arylalkynyl, cycloalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl and heterocycloalkyl;

R^5 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{14}$ and $CR^{15}R^{16}OC(O)R^{14}$;

R^6 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{17}$ and $CR^{18}R^{19}OC(O)R^{17}$;

R^7 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^8 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^9 is independently selected from hydrogen, deuterium, halogen, simple alkyl and alkynyl;

R^{10} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{11} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{12} is independently selected from hydrogen, deuterium and simple alkyl;

R^{13} is independently selected from hydrogen, deuterium and simple alkyl;

R^{14} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl, cycloalkyl, monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, simple alkyl, haloalkyl or heteroalkyl;

R^{15} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{16} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{17} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl and cycloalkyl, monocyclic aryl, multicyclic aryl, monocyclic heteroaryl or multicyclic heteroaryl;

R^{18} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{19} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

n is 0 or more;

m is 0 or more;

o is 0, 1, 2, or 3;

p is 0, 1, 2, or 3;

t is 0, 1, or 2;

u is 0, 1, or 2;

a Formula (I) stereoisomer, tautomer, or a Formula (I) prodrug or Formula (I) free base, or a Formula (I) pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

2. A compound according to Formula (II):



(II)

Wherein

X is absent or present and when present is selected from the group consisting of C(O), C(S), $S(O)_2$, $(CR^7R^8)_n$, O, N, NR^1, S and S(O);

Y is absent or present and when present is $(CR^7R^8)_n$;

Z is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, and alkynyl, $(CR^{10}R^{11})_oNR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)O(CR^{12}R^{13})_p$,

$(CR^{10}R^{11})_oNR^9C(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oO(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oS(O)_n(CR^{12}R^{13})_p$ and cycloalkyl;

W is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, OR^9, O, NR^9R^{10} , NR^9, $C(O)R^9$, $C(O)NR^9$, $NR^9C(O)$, $C(O)OR^9$, $OC(O)R^9$ and heterocyclcoalkyl;

Q is absent or present and when present is selected from O, S, NR^1, CR^1, $(CR^{14}R^{15})_t$ and C(O);

A is selected from a substituted or unsubstituted carbon and nitrogen;

B is selected from a substituted or unsubstituted carbon and nitrogen;

C is selected from a substituted or unsubstituted carbon and nitrogen;

D is selected from a substituted or unsubstituted carbon and nitrogen;

E is selected from a substituted or unsubstituted carbon and nitrogen;
the bond between Q and X is a single or double bond;

R^1 is selected from hydrogen, alkyl, cycloalkyl, haloalkyl, heteroalkyl, heterohaloalkyl and heteroalkynyl;

R^2 is selected from hydrogen, deuterium, halogen, CN, alkyl, cycloalkyl, haloalkyl, heteroalkyl, aryl, heteroaryl, heterohaloalkyl and heteroalkynyl;

R^3 is independently selected from the group consisting of: hydrogen, deuterium, halogen, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl and C(O);

R^4 is independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxyl, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl and heterocycloalkyl;

R^5 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{14}$ and $CR^{15}R^{16}OC(O)R^{14}$;

R^7 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^8 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^9 is independently selected from hydrogen, deuterium, halogen, simple alkyl and alkynyl;

R^{10} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{11} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{12} is independently selected from hydrogen, deuterium and simple alkyl;

R^{13} is independently selected from hydrogen, deuterium and simple alkyl;

R^{14} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl, cycloalkyl, monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, simple alkyl, haloalkyl or heteroalkyl;

R^{15} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{16} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

n is 0 or more;

m is 0 or more;

o is 0, 1, 2, or 3;

p is 0, 1, 2, or 3;

t is 0, 1, or 2;

a Formula (II) stereoisomer, tautomer, or a Formula (II) prodrug or Formula (II) free base, or a Formula (II) pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

3. A compound according to Formula (IIIa) or (IIIb):



(IIIa)



IIIb

Wherein

X is absent or present and when present selected from the group consisting of C(O), C(S), $S(O)_2$, $(CR^7R^8)_n$, O, N, NR^1, S and S(O);

Y is absent or present and when present is $(CR^7R^8)_n$;

Z is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, $(CR^{10}R^{11})_oNR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)NR^9(CR^{12}R^{13})_p$,

$(CR^{10}R^{11})_oC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oO(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oS(O)_n(CR^{12}R^{13})_p$ and cycloalkyl;

W is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, OR^9, O, NR^9R^{10} , NR^9, $C(O)R^9$, $C(O)NR^9$, $NR^9C(O)$, $C(O)OR^9$, $OC(O)R^9$ and heterocycloalkyl;

Q is absent or present and when present is selected from O, S, NR^1, CR^1, $(CR^{14}R^{15})_t$ and C(O);

the bond between Q and X is a single or double bond;

A is selected from a substituted or unsubstituted carbon and nitrogen;

R^1 is selected from hydrogen, alkyl, cycloalkyl, haloalkyl, heteroalkyl, heterohaloalkyl and heteroalkynyl;

R^2 is selected from hydrogen, deuterium, halogen, CN, alkyl, cycloalkyl, haloalkyl, heteroalkyl, aryl, heteroaryl, heterohaloalkyl and heteroalkynyl;

R^4 is independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxyl, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl and heterocycloalkyl;

R^5 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{14}$ and $CR^{15}R^{16}OC(O)R^{14}$;

R^7 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^8 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^9 is independently selected from hydrogen, deuterium, halogen, simple alkyl and alkynyl;

R^{10} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{11} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{12} is independently selected from hydrogen, deuterium and simple alkyl;

R^{13} is independently selected from hydrogen, deuterium and simple alkyl;

R^{14} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl, cycloalkyl, monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, simple alkyl, haloalkyl or heteroalkyl;

R^{15} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{16} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

n is 0 or more;

m is 0 or more;

o is 0, 1, 2, or 3;

p is 0, 1, 2, or 3;

t is 0, 1, or 2;

a Formula (IIIa) or (IIIb) stereoisomer, tautomer, or a Formula (IIIa) or (IIIb) prodrug or Formula (IIIa) or (IIIb) free base, or a Formula (IIIa) or (IIIb) pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

4. A compound according to Formula (IV):



(IV)

Wherein

X is absent or present and when present selected from the group consisting of C(O), C(S), $S(O)_2$, $(CR^7R^8)_n$, O, N, NR^1, S and S(O);

Y is absent or present and when present is $(CR^7R^8)_n$;

Z is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, $(CR^{10}R^{11})_oNR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oO(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oS(O)_n(CR^{12}R^{13})_p$ and cycloalkyl;

W is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, OR^9, O, NR^9R^{10} , NR^9, $C(O)R^9$, $C(O)NR^9$, $NR^9C(O)$, $C(O)OR^9$, $OC(O)R^9$ and heterocycloalkyl;

Q is absent or present and when present is selected from O, S, NR^1, CR^1, $(CR^{14}R^{15})_t$ and C(O);

the bond between Q and X is a single or double bond;

A is selected from a substituted or unsubstituted carbon, oxygen, sulfur and nitrogen;

B is selected from a substituted or unsubstituted carbon and nitrogen;

C is selected from a substituted or unsubstituted carbon and nitrogen;



is selected from



,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


, and


;

Each of Ri, Rii, Riii, Riv, and Rv, independently, is hydrogen, halogen, cyano group, amino group, amido group, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, or is a moiety selected from C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, and heteroaryl, each of which is optionally mono-, di-, or tri-substituted with halogen, nitro group, cyano group, amino group, amido gruop, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, C_{2-6} alkynyl,

aryl, or heteroaryl, or optionally fused with C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, or heteroaryl;

R^1 is selected from hydrogen, alkyl, cycloalkyl, haloalkyl, heteroalkyl, heterohaloalkyl and heteroalkynyl;

R^2 is selected from hydrogen, deuterium, halogen, CN, alkyl, cycloalkyl, haloalkyl, heteroalkyl, aryl, heteroaryl, heterohaloalkyl and heteroalkynyl;

R^4 is independently selected from the group consisting of: hydrogen, deuterium, halogen, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl and heterocycloalkyl;

R^5 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{14}$ and $CR^{15}R^{16}OC(O)R^{14}$;

R^7 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^8 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^9 is independently selected from hydrogen, deuterium, halogen, simple alkyl and alkynyl;

R^{10} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{11} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{12} is independently selected from hydrogen, deuterium and simple alkyl;

R^{13} is independently selected from hydrogen, deuterium and simple alkyl;

R^{14} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl and cycloalkyl, monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, simple alkyl, haloalkyl or heteroalkyl;

R^{15} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{16} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

n is 0 or more;

m is 0 or more;

o is 0, 1, 2, or 3;

p is 0, 1, 2, or 3;

t is 0, 1, or 2;

a Formula (IV) stereoisomer, tautomer, or a Formula (IV) prodrug or Formula (IV) free base, or a Formula (IV) pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

5. A compound according to Formula (V):



(V)

Wherein

X is absent or present and when present selected from the group consisting of C(O), C(S), $S(O)_2$, $(CR^7R^8)_n$, O, N, NR^1, S and S(O);

Y is absent or present and when present is $(CR^7R^8)_n$;

Z is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, $(CR^{10}R^{11})_oNR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oO(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oS(O)_n(CR^{12}R^{13})_p$ and cycloalkyl;

W is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, OR^9, O, NR^9R^{10} , NR^9, $C(O)R^9$, $C(O)NR^9$, $NR^9C(O)$, $C(O)OR^9$, $OC(O)R^9$ and heterocycloalkyl;

Q is absent or present and when present is selected from O, S, NR^1, CR^1, $(CR^{14}R^{15})_t$ and C(O);

the bond between Q and X is a single or double bond;

A is selected from a substituted or unsubstituted carbon and nitrogen;

B is selected from a substituted or unsubstituted carbon and nitrogen;

C is selected from a substituted or unsubstituted carbon and nitrogen;



is selected from



,


,


,



,


,


,



,


,


, and


;

Each of Ri, Rii, Riii, Riv, and Rv, independently, is hydrogen, halogen, cyano group, amino group, amido group, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, or is a moiety selected from C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, and heteroaryl, each of which is optionally mono-, di-, or tri-substituted with halogen, nitro group, cyano group, amino group, amido gruop, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, or heteroaryl, or optionally fused with C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, or heteroaryl;

R^1 is selected from hydrogen, alkyl, cycloalkyl, haloalkyl, heteroalkyl, heterohaloalkyl and heteroalkynyl;

R^2 is selected from hydrogen, deuterium, halogen, CN, alkyl, cycloalkyl, haloalkyl, heteroalkyl, aryl, heteroaryl, heterohaloalkyl and heteroalkynyl;

R^4 is independently selected from the group consisting of: hydrogen, deuterium, halogen, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl and heterocycloalkyl;

R^5 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{14}$ and $CR^{15}R^{16}OC(O)R^{14}$;

R^7 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^8 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^9 is independently selected from hydrogen, deuterium, halogen, simple alkyl and alkynyl;

R^{10} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{11} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{12} is independently selected from hydrogen, deuterium and simple alkyl;

R^{13} is independently selected from hydrogen, deuterium and simple alkyl;

R^{14} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl and cycloalkyl, monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, simple alkyl, haloalkyl or heteroalkyl;

R^{15} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{16} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

n is 0 or more;

m is 0 or more;

o is 0, 1, 2, or 3;

p is 0, 1, 2, or 3;

t is 0, 1, or 2;

a Formula (V) stereoisomer, tautomer, or a Formula (V) prodrug or Formula (V) free base, or a Formula (V) pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

6. A compound according to Formula (VI):



(VI)

Wherein

X is absent or present and when present selected from the group consisting of C(O), C(S), $S(O)_2$, $(CR^7R^8)_n$, O, N, NR^1, S and S(O);

Y is absent or present and when present is $(CR^7R^8)_n$;

Z is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, $(CR^{10}R^{11})_oNR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oO(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oS(O)_n(CR^{12}R^{13})_p$ and cycloalkyl;

W is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, OR^9, O, NR^9R^{10} , NR^9, $C(O)R^9$, $C(O)NR^9$, $NR^9C(O)$, $C(O)OR^9$, $OC(O)R^9$ and heterocycloalkyl;

Q is absent or present and when present is selected from O, S, NR^1, CR^1, $(CR^{14}R^{15})_t$, C(O), cycloalkyl and heterocycloalkyl;

the bond between Q and X is a single or double bond;

A is selected from a substituted or unsubstituted carbon and nitrogen;

B is selected from a substituted or unsubstituted carbon and nitrogen;

C is selected from a substituted or unsubstituted carbon and nitrogen;

D is selected from a substituted or unsubstituted carbon and nitrogen;

E is selected from a substituted or unsubstituted carbon and nitrogen;



is selected from



,


,


,



,


,


,



,


,


,



,


,


,



, ,


,


,



,


, and



;

Each of Ri, Rii, Riii, Riv, Rv, Rvi, Rvii, and Rviii, independently, is hydrogen, halogen, cyano group, amino group, amido group, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, or is a moiety selected from C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, and heteroaryl, each of which is optionally mono-, di-, or tri-substituted with halogen, nitro group, cyano group, amino group, amido gruop, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, or heteroaryl, or optionally fused with C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, or heteroaryl;

Gi is selected from CH_2, O and SO_2;

Gii is selected from CH_2 and O;

the bond between Gi and Gii is a single or double bond;

R^1 is selected from hydrogen, alkyl, cycloalkyl, haloalkyl, heteroalkyl, heterohaloalkyl and heteroalkynyl;

R^2 is selected from hydrogen, deuterium, halogen, CN, alkyl, cycloalkyl, haloalkyl, heteroalkyl, aryl, heteroaryl, heterohaloalkyl and heteroalkynyl;

R^4 is independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxyl, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl and heterocycloalkyl;

R^5 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{14}$ and $CR^{15}R^{16}OC(O)R^{14}$;

R^7 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^8 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^9 is independently selected from hydrogen, deuterium, halogen, simple alkyl and alkynyl;

R^{10} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{11} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{12} is independently selected from hydrogen, deuterium and simple alkyl;

R^{13} is independently selected from hydrogen, deuterium and simple alkyl;

R^{14} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl and cycloalkyl, monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, simple alkyl, haloalkyl or heteroalkyl;

R^{15} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{16} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

n is 0 or more;

m is 0 or more;

o is 0, 1, 2, or 3;

p is 0, 1, 2, or 3;

t is 0, 1, or 2;

a Formula (VI) stereoisomer, tautomer, or a Formula (VI) prodrug or Formula (VI) free base, or a Formula (VI) pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

7. A compound according to Formula (VI):



(VI)

Wherein

X is selected from the group consisting of C(O) and $S(O)_2$;

Y is absent or present and when present is $(CR^7R^8)_n$;

W is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, OR^9, O, NR^9R^{10} , NR^9, $C(O)R^9$, $C(O)NR^9$, $NR^9C(O)$, $C(O)OR^9$, $OC(O)R^9$ and heterocycloalkyl;

Q is selected from NR^1, CR^1, $(CR^{14}R^{15})_t$, cycloalkyl and heterocycloalkyl;


is selected from


,

,

,


,

,

,


,

,

,



,


,


,


,


,


,


,


, and


;

Each of Ri, Rii, Riii, Riv, Rv, Rvi, Rvii, and Rviii, independently, is hydrogen, halogen, cyano group, amino group, amido group, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, or is a moiety selected from C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, and heteroaryl, each of which is optionally mono-, di-, or tri-substituted with halogen, nitro group, cyano group, amino group, amido gruop, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, or heteroaryl, or optionally fused with C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, or heteroaryl;

Gi is selected from CH_2, O, and SO_2;

Gii is selected from CH_2 and O;

the bond between Gi and Gii is a single or double bond;

R^1 is selected from hydrogen, alkyl, cycloalkyl, haloalkyl, heteroalkyl, heterohaloalkyl and heteroalkynyl;

R^2 is selected from hydrogen, deuterium, halogen, CN, alkyl, cycloalkyl, haloalkyl, heteroalkyl, aryl, heteroaryl, heterohaloalkyl and heteroalkynyl;

R^4 is independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxyl, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl and heterocycloalkyl;

R^5 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{14}$ and $CR^{15}R^{16}OC(O)R^{14}$;
R^7 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^8 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^9 is independently selected from hydrogen, deuterium, halogen, simple alkyl and alkynyl;
R^{10} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{14} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl, cycloalkyl, monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, simple alkyl, haloalkyl or heteroalkyl;

R^{15} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{16} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

m is 0 or more;

t is 0, 1, or 2;

a Formula (VI) stereoisomer, tautomer, or a Formula (VI) prodrug or Formula (VI) free base, or a Formula (VI) pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

8. A compound according to Formula (VI):



(VI)

wherein

X is selected from the group consisting of C(O) and$S(O)_2$;

Y is CH_2;

W is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, OR^9, O, NR^9R^{10} , NR^9, $C(O)R^9$, $C(O)NR^9$, $NR^9C(O)$, $C(O)OR^9$, $OC(O)R^9$ and heterocycloalkyl;

Q is selected from NR^1, CR^1, or $(CR^{14}R^{15})_t$, cycloalkyl and heterocycloalkyl;



is selected from



,


,


,


,


,


,


,


,


,


,


,


,



,


,


,


,


, and


;

Each of Ri, Rii, Riii, Riv, Rv, Rvi, Rvii, and Rviii, independently, is hydrogen, halogen, cyano group, amino group, amido group, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, or is a moiety selected from C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, and heteroaryl, each of which is optionally mono-, di-, or tri-substituted with halogen, nitro group, cyano group, amino group, amido gruop, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, or heteroaryl, or optionally fused with C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, or heteroaryl;

Gi is selected from CH_2, O and SO_2;

Gii is selected from CH_2 and O;

the bond between Gi and Gii is a single or double bond;

R^1 is selected from hydrogen, alkyl, cycloalkyl, haloalkyl, heteroalkyl, heterohaloalkyl and heteroalkynyl;

R^2 is selected from hydrogen and alkyl;

R^4 is independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxyl, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl and heterocycloalkyl;

R^5 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{14}$ and $CR^{15}R^{16}OC(O)R^{14}$;

R^9 is independently selected from hydrogen, deuterium, halogen, simple alkyl and alkynyl;

R^{10} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{14} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl, or cycloalkyl;

R^{15} is independently selected from hydrogen and simple alkyl;

R^{16} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

m is 0 or more;

t is 0, 1, or 2;

a Formula (VI) stereoisomer, tautomer, or a Formula (VI) prodrug or Formula (VI) free base, or a Formula (VI) pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

9. A compound according to Formula (VII):



(VII)

wherein

X is absent or present and when present selected from the group consisting of C(O), C(S), $S(O)_2$, $(CR^7R^8)_n$, O, N, NR^1, S and S(O);

Y is absent or present and when present is selected from the group consisting of $(CR^7R^8)_n$;

Z is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, $(CR^{10}R^{11})_oNR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oC(O)O(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oOC(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oNR^9C(O)O(CR^{12}R^{13})_p$,

$(CR^{10}R^{11})_oNR^9C(O)NR^9(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oO(CR^{12}R^{13})_p$, $(CR^{10}R^{11})_oS(O)_n(CR^{12}R^{13})_p$ and cycloalkyl;

J is absent or present and when present is selected from alkyl, haloalkyl, $C(O)NR^1$, $NR^1C(O)$, NR^7, NR^7R^8, $C(CR^7R^8)_nNR^1$ and $NR^1C(CR^7R^8)_n$;

W is absent or present and when present is selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, OR^9, O, NR^9R^{10} , NR^9, CR^9, CR^9R^{10}, $C(O)R^9$, $C(O)NR^9$, $NR^9C(O)$, $C(O)NR^9R^{10}$, $NR^9R^{10}C(O)$, $C(O)OR^9$, $OC(O)R^9$ and heterocycloalkyl;

Q is absent or present and when present is selected from O, S, NR^1, CR^1, $(CR^{14}R^{15})_t$ and C(O);

ring 

is selected from the group consisting of monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, monocyclic carbocyclic, multicyclic carbocyclic, monocyclic heterocyclic, and multicyclic heterocyclic ring systems;

ring 

is selected from the group consisting of monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, monocyclic carbocyclic, multicyclic carbocyclic, monocyclic heterocyclic, and multicyclic heterocyclic ring systems;

the bond between Q and X is a single or double bond;

R^1 is selected from hydrogen, alkyl, cycloalkyl, haloalkyl, heteroalkyl, heterohaloalkyl and heteroalkynyl;

R^2 is selected from hydrogen, deuterium, halogen, CN, alkyl, cycloalkyl, haloalkyl, heteroalkyl, aryl, heteroaryl, heterohaloalkyl and heteroalkynyl;

R^3 is independently selected from the group consisting of: hydrogen, deuterium, halogen, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl and C(O);

R^4 is independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxyl, CN, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl and heterocycloalkyl;

R^5 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{14}$ and $CR^{15}R^{16}OC(O)R^{14}$;

R^6 is selected from hydrogen, simple alkyl and a prodrug moiety. Said prodrug moiety may be selected from $C(O)R^{17}$ and $CR^{18}R^{19}OC(O)R^{17}$;

R^7 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^8 is independently selected from hydrogen, deuterium, halogen, simple alkyl and haloalkyl;

R^9 is independently selected from hydrogen, deuterium, halogen, simple alkyl and alkynyl;

R^{10} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{11} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{12} is independently selected from hydrogen, deuterium and simple alkyl;

R^{13} is independently selected from hydrogen, deuterium and simple alkyl;

R^{14} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl and cycloalkyl, monocyclic aryl, multicyclic aryl, monocyclic heteroaryl, multicyclic heteroaryl, simple alkyl, haloalkyl or heteralkyl;

R^{15} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{16} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{17} is a straight chain or branched alkyl group of 3 to 28 carbons, heterocycloalkyl and cycloalkyl, monocyclic aryl, multicyclic aryl, monocyclic heteroaryl or multicyclic heteroaryl;

R^{18} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{19} is independently selected from hydrogen, deuterium, halogen and simple alkyl;

R^{20} is independently selected from the group consisting of: hydrogen, deuterium, halogen, CN, C(O), alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl and heterocycloalkyl;

n is 0 or more;

m is 0 or more;

o is 0, 1, 2, or 3;

p is 0, 1, 2, or 3;

t is 0, 1, or 2;

u is 0, 1, or 2;

k is 0, 1, or 2;

a Formula (VII) stereoisomer, tautomer, or a Formula (VII) prodrug or Formula (VII) free base, or a Formula (VII) pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

10. A compound according to claim 1, wherein ring 

is multicyclic heteroaryl.

11. A compound according to claim 1, wherein ring  is tricyclic heteroaryl.

12. A compound according to claim 1,

Wherein  is selected from

, , ,

, , ,

, , ,

, , ,

, , ,



,


,


,


,


, and


;

Each of Ri, Rii, Riii, Riv, Rv, Rvi, Rvii, and Rviii, independently, is hydrogen, halogen, cyano group, amino group, amido group, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, or is a moiety selected from C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, and heteroaryl, each of which is optionally mono-, di-, or tri-substituted with halogen, nitro group, cyano group, amino group, amido gruop, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, or heteroaryl, or optionally fused with C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, or heteroaryl;

Gi is selected from CH2, O and SO2;

Gii is selected from CH2 and O; and

the bond between Gi and Gii is a single or double bond.

13. A compound according to claim 1, wherein ring 

is bicyclic heteroaryl.

14. A compound according to claim 1,

wherein 

is selected from


W
Riv
O
Z
Riii
Rii
Ri
,

W
Ri
Riv
Z
Riii
O
Rii
,

Riii
Z
W
Ri
Rii
N
O
,

W
Ri
Riv
Z
Riii
S
Rii
,

W
Riv
S
Z
Riii
Rii
Ri
,

Riii
Z
W
Ri
Rii
N
S
,

Rv
Z
W
Ri
Riv
N
Riii
Rii
,

Rv
Z
W
N
Ri
Riv
Riii
Rii
,

Rv
Z
Riv
N
Ri
W
Riii
Rii
,

Rv
Ri
W
Z
Riv
N
Riii
Rii
,

Rv
Ri
W
Z
Riv
N
Riii
Rii
,

Riv
Ri
W
Z
Riii
N
Rii
,

Riv
Z
W
Ri
Riii
N
N
Rii
,

Riv
Z
W
N
Ri
Riii
N
Rii
,

Z
Riv
N
N
Ri
W
Riii
Rii
,

Riv
Z
W
N
Ri
Riii
N
Rii
,

Riv
Z
Riii
N
Ri
W
N
Rii
,

Z
O
W
Ri
N
S
,

W
Ri
Z
Rv
N
Rii
Riv
Riii
,

Rv
Ri
W
Z
Riv
N
Rii
Riii
,

Rv
Ri
W
Z
Riv
N
Rii
Riii
,

and 

;

Each of Ri, Rii, Riii, Riv, Rv, Rvi, Rvii, and Rviii, independently, is hydrogen, halogen, cyano group, amino group, amido group, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, or is a moiety selected from C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, and heteroaryl, each of which is optionally mono-, di-, or tri-substituted with halogen, nitro group, cyano group, amino group, amido gruop, C_{1-6} alkyl, C_{1-6} alkoxyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, or heteroaryl, or optionally fused with C_{3-10} cycloalkyl, C_{1-10} heterocycloalkyl, aryl, or heteroaryl;

15. A compound according to claim 1, wherein ring 

is a monocyclic heteroaryl.

16. A compound according to claim 9, wherein R^4 is selected from a bicyclic heteroarylalkynyl and monocyclic heteroarylalkynyl.

17. A compound according to claim 9, wherein ring 

is a monocyclic or bicyclic heteroaryl.

18. A compound according to claim 9, wherein ring 

is a monocyclic heteroaryl or bicyclic heteroaryl.

19. A compound according to claim 2 or 3 is selected from:

(*S,E*)-2-imino-3,6-dimethyl-6-(2-(5-(prop-1-yn-1-yl)pyridin-3-yl)vinyl)tetrahydropyrimidin-4(1*H*)-one;

(*S)*-but-2-yn-1-yl 3-(2-imino-1,4-dimethyl-6-oxohexahydropyrimidin-4-yl)-1*H*-pyrrole-1-carboxylate;

(*R*)-but-2-yn-1-yl 1-(2-imino-1,4-dimethyl-6-oxohexahydropyrimidin-4-yl)-1*H*-pyrrole-3-carboxylate;

(*R*)-but-2-yn-1-yl 1-((4-ethyl-2-imino-1-methyl-6-oxohexahydropyrimidin-4-yl)methyl)-1*H*-pyrrole-3-carboxylate; and

(*S*)-but-2-yn-1-yl 1-((4-ethyl-2-imino-1-methyl-6-oxohexahydropyrimidin-4-yl)methyl)-1*H*-pyrrole-3-carboxylate;

a stereoisomer, tautomer, or a prodrug or free base, or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

20. A compound according to claim 4 or 5 is selected from:

(*S*)-6-(7-hydroxybenzofuran-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-imino-6-(7-methoxybenzofuran-2-yl)-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(7-(but-2-yn-1-yloxy)benzofuran-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-imino-3,6-dimethyl-6-(3-(prop-1-yn-1-yl)-1*H*-indol-5-yl)tetrahydropyrimidin-4(1H)-one;

(*S*)-2-imino-3,6-dimethyl-6-(6-(prop-1-yn-1-yl)quinolin-3-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-imino-3,6-dimethyl-6-(3-(prop-1-yn-1-yl)quinolin-6-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(2-((S)-2-hydroxypent-3-yn-2-yl)benzo[*d*]oxazol-5-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-imino-3,6-dimethyl-6-(2-(2-methylpent-3-yn-2-yl)benzo[*d*]oxazol-5-yl)tetrahydropyrimidin-4(1*H*)-one; and

(*R*)-2-amino-3,6-dimethyl-6-(2-(2-methylpent-3-yn-2-yl)-1H-benzo[*d*]imidazol-6-yl)-5,6-dihydropyrimidin-4(3*H*)-one;

a stereoisomer, tautomer, or a prodrug or free base, or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

21. A compound according to claim 6 is selected from:

(*S*)-2-Imino-3,6-dimethyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*,*Z*)-*N*-(1,4-Dimethyl-6-oxo-4-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-2(1*H*)-ylidene)benzamide;

(*S*)-1-Benzoyl-2-imino-3,6-dimethyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*,*Z*)-((1,4-Dimethyl-6-oxo-4-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-2(1*H*)-ylidene)amino)methyl benzoate;

(*S*)-(2-Imino-3,6-dimethyl-4-oxo-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-1(2*H*)-yl)methyl benzoate;

(*S*,*Z*)-*N*-(1,4-Dmethyl-6-oxo-4-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-2(1*H*)-ylidene)palmitamide;

(*S*,*Z*)-((1,4-Dimethyl-6-oxo-4-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-2(1*H*)-ylidene)amino)methyl dodecanoate;

(*S*)-2-Imino-3,6-dimethyl-1-palmitoyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)te
trahydropyrimidin-4(1*H*)-one;

(*S*)-(2-Imino-3,6-dimethyl-4-oxo-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrah
ydropyrimidin-1(2*H*)-yl)methyl dodecanoate;

(*S*)-2-Imino-3,6-dimethyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]furan-2-yl)tetrahydropyrimi
din-4(1*H*)-one;

(*R*)-3-Imino-2,2,5-trimethyl-5-(7-methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)thio
morpholine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-(2-methyl-6,11-dihydro-5*H*-benzo[b]pyrido[3,2-f]azepin-
9-yl)thiomorpholine 1,1-dioxide;

(*R*)-5-(7Fluoro-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)-3-imino-2,2,5-trimethylthiom
orpholine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-(7-methyl-5,11-dihydrodibenzo[b,e][1,4]oxazepin-3-yl)thi
omorpholine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-(3-methyl-5,11-dihydrodibenzo[b,e][1,4]oxazepin-7-yl)thi
omorpholine 1,1-dioxide;

(*R*)-7-(5-Imino-3,6,6-trimethyl-1,1-dioxidothiomorpholin-3-yl)-3-methyl-5,11-dihydrodib
enzo[b,e][1,4]thiazepine 10,10-dioxide;

(*R*)-5-((1a*S*,10b*R*)-4-Fluoro-1,1a,6,10b-tetrahydrobenzo[b]cyclopropa[d]pyrido[3,2-f]a
zepin-8-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-5-(2-Fluoro-7-methyl-5H-dibenzo[b,f]azepin-3-yl)-3-imino-2,2,5-trimethylthiomorp
holine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-(7-methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)thio
morpholine 1,1-dioxide;

(*S*)-6-(3-chloro-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetra
hydropyrimidin-4(1*H*)-one;

(*S*)-6-(3-fluoro-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(9-fluoro-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(5,5-dioxido-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(6*S*)-2-imino-3,6-dimethyl-6-(5-oxido-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(9,9-Dimethyl-6-(prop-1-yn-1-yl)-9H-fluoren-3-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(9,9-Difluoro-6-(prop-1-yn-1-yl)-9*H*-fluoren-3-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-8-(2-Imino-1,4-dimethyl-6-oxohexahydropyrimidin-4-yl)dibenzo[b,d]thiophene-2-carbonitrile;

(*S*)-2-imino-6-(8-(3-methoxyprop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(8-(3-hydroxyprop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(8-Bromodibenzo[b,d]thiophen-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(8-cyclopropyldibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-8-(2-Imino-1,4-dimethyl-6-oxohexahydropyrimidin-4-yl)dibenzo[b,d]thiophene-2-carboxamide;

(*S*)-6-(8-(Diethylamino)dibenzo[b,d]thiophen-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-Imino-3,6-dimethyl-6-(8-(trifluoromethyl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*R*)-6-Cyclopropyl-2-imino-3-methyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*R*)-5,5-difluoro-4-methyl-4-(8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-1,3-oxazinan-2-imine;

(*R*)-3-imino-2,2,5-trimethyl-5-(8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)thiomorpholine 1,1-dioxide;

(*R*)-3-Imino-2,5-dimethyl-5-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-1,2,4-thiadiazinane 1,1-dioxide;

(*S*)-3-(2,2-Difluoroethyl)-2-imino-6-methyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-Imino-3-(2-methoxyethyl)-6-methyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*R*)-5-(3-fluoro-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-3-imino-2,
2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-3-Imino-1,5-dimethyl-5-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)piperazin-2-one;

(*R*)-5-(4-Fluoro-8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-5-(7-fluoro-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-10-Imino-8-methyl-8-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-6-thia-9-azaspiro[4.5]decane 6,6-dioxide;

(*R*)-8-Imino-6-methyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-4-thia-7-azaspiro[2.5]octane 4,4-dioxide;

((*R,E*)-3-Imino-2,2,5-trimethyl-5-(8-(prop-1-en-1-yl)dibenzo[b,d]thiophen-2-yl)thiomorpholine 1,1-dioxide; and

(*R*)-6-(7-Fluoro-8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-8-imino-6-methyl-4-thia-7-azaspiro[2.5]octane 4,4-dioxide;

a stereoisomer, tautomer, or a prodrug or free base, or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

22. A compound according to claim 9 is selected from:

(*S*)-N-(4-Chloro-3-(2-imino-1,4-dimethyl-6-oxohexa hydropyrimidin-4-yl)phenyl)-5-(prop-1-yn-1-yl)picolinamide;

(*S*)-N-(4-Fluoro-3-(2-imino-1,4-dimethyl-6-oxohexahydropyrimidin-4-yl)phenyl)-5-(prop-1-yn-1-yl)picolinamide;

(*S*)-N-(4-chloro-3-(2-imino-1,4-dimethyl-6-oxohexahydropyrimidin-4-yl)phenyl)-N-methyl-5-(prop-1-yn-1-yl)picolinamide;

(*S*)-6-(4-((*R*)-1-fluoro-1-(4-(prop-1-yn-1-yl)-1*H*-imidazol-1-yl)ethyl)phenyl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(6*S*)-2-imino-3,6-dimethyl-6-(4-(1-(4-(prop-1-yn-1-yl)-1*H*-imidazol-1-yl)ethyl)phenyl)tetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(2-chloro-5-((1,1-dioxido-6-(prop-1-yn-1-yl)thieno[3,2-*b*]pyridin-3-yl)amino)phenyl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(2-chloro-5-((3-(prop-1-yn-1-yl)quinolin-8-yl)amino)phenyl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(2-chloro-5-((6-(prop-1-yn-1-yl)thieno[3,2-*b*]pyridin-3-yl)amino)phenyl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(2-chloro-5-(((5-(prop-1-yn-1-yl)pyridin-2-yl)methyl)amino)phenyl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(2-chloro-5-(((*R*)-1-(5-(prop-1-yn-1-yl)pyridin-2-yl)ethyl)amino)phenyl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(2-chloro-5-((3-(5-(prop-1-yn-1-yl)pyridin-2-yl)oxetan-3-yl)amino)phenyl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-imino-3,6-dimethyl-6-((1*R*,2*R*)-2-((5-(prop-1-yn-1-yl)benzo[*d*]isoxazol-3-yl)methyl) cyclopropyl)tetrahydropyrimidin-4(1*H*)-one;

(*R*)-5-(2-(1,3-Dimethyl-1*H*-pyrazol-4-yl)benzo[b]thiophen-6-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-5-(2-(1,3-Dimethyl-1*H*-pyrazol-4-yl)-2*H*-indazol-5-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-((1*R*,2*R*)-2-((5-(prop-1-yn-1-yl)benzo[b]thiophen-3-yl)methyl)cyclopropyl)thiomorpholine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-((*R*)-1-(4-(prop-1-yn-1-yl)pyridin-2-yl)pyrrolidin-3-yl)thiomorpholine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-((1*R*,2*R*)-2-((5-(prop-1-yn-1-yl)benzo[d]isoxazol-3-yl)methyl)cyclopropyl)thiomorpholine 1,1-dioxide;

(*R*)-5-(2-(1,3-Dimethyl-1*H*-pyrazol-5-yl)benzo[d]thiazol-6-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-5-(2-(1,3-Dimethyl-1*H*-pyrazol-5-yl)benzo[d]oxazol-6-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-5-(2-(2,4-Dimethyloxazol-5-yl)-2*H*-indazol-5-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-5-(2-(2,4-Dimethyloxazol-5-yl)-1*H*-benzo[d]imidazol-5-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-5-(2-(2,4-Dimethyloxazol-5-yl)indolizin-7-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide; and

(*R*)-5-(2-(2,4-Dimethyloxazol-5-yl)-1-methyl-1*H*-benzo[d]imidazol-5-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

a stereoisomer, tautomer, or a prodrug or free base, or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

23. A compound according to claim 1 is selected from:

(*S,E*)-2-imino-3,6-dimethyl-6-(2-(5-(prop-1-yn-1-yl)pyridin-3-yl)vinyl)tetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(7-hydroxybenzofuran-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-imino-6-(7-methoxybenzofuran-2-yl)-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(7-(but-2-yn-1-yloxy)benzofuran-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-Imino-3,6-dimethyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*,*Z*)-*N*-(1,4-Dimethyl-6-oxo-4-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-2(1*H*)-ylidene)benzamide;

(*S*)-1-Benzoyl-2-imino-3,6-dimethyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*,*Z*)-((1,4-Dimethyl-6-oxo-4-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-2(1*H*)-ylidene)amino)methyl benzoate;

(*S*)-(2-Imino-3,6-dimethyl-4-oxo-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-1(2*H*)-yl)methyl benzoate;

(*S*,*Z*)-*N*-(1,4-Dmethyl-6-oxo-4-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-2(1*H*)-ylidene)palmitamide;

(*S*,*Z*)-((1,4-Dimethyl-6-oxo-4-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-2(1*H*)-ylidene)amino)methyl dodecanoate;

(*S*)-2-Imino-3,6-dimethyl-1-palmitoyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*)-(2-Imino-3,6-dimethyl-4-oxo-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-1(2*H*)-yl)methyl dodecanoate;

(*S*)-2-Imino-3,6-dimethyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]furan-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*R*)-3-Imino-2,2,5-trimethyl-5-(7-methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)thiomorpholine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-(2-methyl-6,11-dihydro-5*H*-benzo[b]pyrido[3,2-f]azepin-9-yl)thiomorpholine 1,1-dioxide;

(*R*)-5-(7Fluoro-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-(7-methyl-5,11-dihydrodibenzo[b,e][1,4]oxazepin-3-yl)thiomorpholine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-(3-methyl-5,11-dihydrodibenzo[b,e][1,4]oxazepin-7-yl)thiomorpholine 1,1-dioxide;

(*R*)-7-(5-Imino-3,6,6-trimethyl-1,1-dioxidothiomorpholin-3-yl)-3-methyl-5,11-dihydrodibenzo[b,e][1,4]thiazepine 10,10-dioxide;

(*R*)-5-((1a*S*,10b*R*)-4-Fluoro-1,1a,6,10b-tetrahydrobenzo[b]cyclopropa[d]pyrido[3,2-f]azepin-8-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-5-(2-Fluoro-7-methyl-5H-dibenzo[b,f]azepin-3-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-3-Imino-2,2,5-trimethyl-5-(7-methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)thiomorpholine 1,1-dioxide;

(*S*)-6-(3-chloro-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetra hydropyrimidin-4(1*H*)-one;

(*S*)-6-(3-fluoro-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetra hydropyrimidin-4(1*H*)-one;

(*S*)-6-(9-fluoro-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetra hydropyrimidin-4(1H)-one;

(*S*)-6-(5,5-dioxido-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethylte trahydropyrimidin-4(1*H*)-one;

(6*S*)-2-imino-3,6-dimethyl-6-(5-oxido-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)tetr ahydropyrimidin-4(1*H*)-one;

(*S*)-6-(9,9-Dimethyl-6-(prop-1-yn-1-yl)-9H-fluoren-3-yl)-2-imino-3,6-dimethyltetrahydr opyrimidin-4(1*H*)-one;

(*S*)-6-(9,9-Difluoro-6-(prop-1-yn-1-yl)-9*H*-fluoren-3-yl)-2-imino-3,6-dimethyltetrahydro pyrimidin-4(1*H*)-one;

(*S*)-8-(2-Imino-1,4-dimethyl-6-oxohexahydropyrimidin-4-yl)dibenzo[b,d] thiophene-2-carbonitrile;

(*S*)-2-Imino-6-(8-(3-methoxyprop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-3,6-dimethyltet rahydropyrimidin-4(1*H*)-one;

(*S*)-6-(8-(3-Hydroxyprop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-2-imino-3,6-dimethyltetr ahydropyrimidin-4(1*H*)-one;

(*S*)-6-(8-Bromodibenzo[b,d]thiophen-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-imino-6-(8-(3-methoxyprop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-3,6-dimethyltetr ahydropyrimidin-4(1*H*)-one;

(*S*)-6-(8-(3-hydroxyprop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetr ahydropyrimidin-4(1*H*)-one;

(*S*)-2-Imino-3,6-dimethyl-6-(8-propyldibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*)-6-(8-cyclopropyldibenzo[*b,d*]thiophen-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-8-(2-Imino-1,4-dimethyl-6-oxohexahydropyrimidin-4-yl)dibenzo[b,d]thiophene-2-carboxamide;

(*S*)-6-(8-(Diethylamino)dibenzo[b,d]thiophen-2-yl)-2-imino-3,6-dimethyltetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-imino-3,6-dimethyl-6-(8-(trifluoromethyl)dibenzo[*b,d*]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*R*)-6-Cyclopropyl-2-imino-3-methyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*R*)-5,5-difluoro-4-methyl-4-(8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-1,3-oxazinan-2-imine;

(*R*)-3-imino-2,2,5-trimethyl-5-(8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)thiomorpholine 1,1-dioxide;

(*R*)-3-Imino-2,5-dimethyl-5-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-1,2,4-thiadiazinane 1,1-dioxide;

(*S*)-3-(2,2-Difluoroethyl)-2-imino-6-methyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*S*)-2-Imino-3-(2-methoxyethyl)-6-methyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)tetrahydropyrimidin-4(1*H*)-one;

(*R*)-5-(3-fluoro-8-(prop-1-yn-1-yl)di benzo[*b,d*]thiophen-2-yl)-3-imino-2,

2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-3-Imino-1,5-dimethyl-5-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)piperazin-2-one;

(*R*)-5-(4-Fluoro-8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-5-(7-fluoro-8-(prop-1-yn-1-yl)dibenzo[*b,d*]thiophen-2-yl)-3-imino-2,2,5-trimethylthiomorpholine 1,1-dioxide;

(*R*)-10-Imino-8-methyl-8-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-6-thia-9-azaspiro[4.5]decane 6,6-dioxide;

(*R*)-8-Imino-6-methyl-6-(8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-4-thia-7-azaspiro[2.5]octane 4,4-dioxide;

((*R,E*)-3-Imino-2,2,5-trimethyl-5-(8-(prop-1-en-1-yl)dibenzo[b,d]thiophen-2-yl)thiomorpholine 1,1-dioxide; and

(*R*)-6-(7-Fluoro-8-(prop-1-yn-1-yl)dibenzo[b,d]thiophen-2-yl)-8-imino-6-methyl-4-thia-7-azaspiro[2.5]octane 4,4-dioxide;

a stereoisomer, tautomer, or a prodrug or free base, or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

24. A compound according to claim 12 wherein X and Y are taken together to form a ring structure 

.

25. A pharmaceutical composition comprising a compound according to claim 1 to 24 in a therapeutically effective amount and a pharmaceutically acceptable excipient.

26. Use of the compound according to claim 1 to 24 in the manufacture of a medicament, wherein the medicament is for treating or preventing an amyloid beta related pathology.

27. The use according to claim 26, wherein said amyloid beta related pathology is Downs syndrome, β-amyloid angiopathy, disorders associated with cognitive impairment, Alzheimer’s disease, memory loss, attention deficit symptoms associated with Alzheimer’s disease, neurodegenerative diseases, pre-senile dementia, senile dementia and dementia associated with Alzheimer’s disease, Parkinson's disease and/or Down’s syndromes, age-related macular degeneration (AMD), glaucoma, olfactory function impairment, traumatic brain injury, progressive muscle diseases, Type II diabetes mellitus and cardiovascular diseases.

28. Use of the compound according to claim 1 to 24 in the manufacture of a medicament, wherein the medicament is for treating or preventing Alzheimer's disease.